| Assessment Status | Rapid Review Complete |
| HTA ID | 20032 |
| Drug | Ibrutinib |
| Brand | Imbruvica® |
| Indication | As a single agent or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). |
| Assessment Process | |
| Rapid review commissioned | 06/07/2020 |
| Rapid review completed | 04/08/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Ibrutinib as a single agent or in combination with obinutuzumab for adult patients with previously untreated CLL compared with the current standard of care. |
